# Picard Medical, Inc. (PMI) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_155bba6c02f442cd535b · retrieved 2026-08-11T15:53:22.508Z

## Overview
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which develops, manufactures, and commercializes the SynCardia Total Artificial Heart (STAH), an implantable system for patients with end-stage heart failure; the STAH is the first artificial heart approved by both the FDA and Health Canada and remains the only commercially available artificial heart in the United States and Ca…

On July 22, 2026, Picard Medical, Inc. received acceptance from NYSE American LLC of its compliance plan to regain compliance with continued listing standards under Sections 1003(a)(i) and (ii). The company had reported stockholders' equity of $3.8 million as of December 31, 2025, a stockholders' deficit of $(1.4) million as of March 31, 2026, and losses in three of its four most recent fiscal years. The acceptance allows Picard Medical to continue listing on NYSE American subject to achieving milestones in the compliance plan and quarterly review by the exchange. The company has a maximum of 18 months from the original notice of noncompliance to regain full compliance, with the compliance period extending through November 8, 2027.

## Terms
- Counterparty: NYSE American LLC

## Key dates
- Announced 2026-07-27 · Expiry 2027-11-08 · Expected close 2027-11-08

## Timeline
- 2026-07-27 · 8-K (0001437749-26-024465): 8-K - Picard Medical, Inc. — *Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which develops, manufactures, and commercializes the SynCardia Total Artificial Heart (STAH), an implantable system for patients with end-stage heart failure; the STAH is the first artificial heart approved by both the FDA and Health Canada and remains the only commercially available artificial heart in the United States and Ca…* On July 22, 2026, Picard Medical, Inc. received acceptance from NYSE American LLC of its compliance plan to regain compliance with continued listing standards under Sections 1003(a)(i) and (ii). The company had reported stockholders' equity of $3.8 million as of December 31, 2025, a stockholders' deficit of $(1.4) million as of March 31, 2026, and losses in three of its four most recent fiscal years. The acceptance allows Picard Medical to continue listing on NYSE American subject to achieving milestones in the compliance plan and quarterly review by the exchange. The company has a maximum of 18 months from the original notice of noncompliance to regain full compliance, with the compliance period extending through November 8, 2027.
  https://www.sec.gov/Archives/edgar/data/2030617/0001437749-26-024465.txt

## Citations
- 0001437749-26-024465 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000143774926024465